{"id":69042,"date":"2026-06-29T21:54:39","date_gmt":"2026-06-29T13:54:39","guid":{"rendered":"https:\/\/flcube.com\/?p=69042"},"modified":"2026-06-29T21:54:40","modified_gmt":"2026-06-29T13:54:40","slug":"akeso-biopharma-ships-first-batch-of-gumokimab-for-psoriasis-following-nmpa-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69042","title":{"rendered":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Akeso Biopharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/9926:HKG\">HKG: 9926<\/a>)<\/strong> announced on June 26, 2026, that <strong>Qiyoukang (gumokimab, AK111)<\/strong> has completed its <strong>first batch shipment<\/strong> in China following <strong>National Medical Products Administration (NMPA) approval<\/strong> for the treatment of <strong>adult patients with moderate-to-severe plaque psoriasis<\/strong>. The novel humanized IL-17 monoclonal antibody represents Akeso&#8217;s latest commercial launch in the competitive autoimmune disease market.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-commercial-milestones\" class=\"wp-block-heading\">Regulatory &amp; Commercial Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Milestone<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Jun 2026<\/strong><\/td><td>NMPA Approval + First Shipment<\/td><td>Moderate-to-severe plaque psoriasis<\/td><\/tr><tr><td><strong>Jun 2026<\/strong><\/td><td>NDA Acceptance<\/td><td>Active ankylosing spondylitis (second indication)<\/td><\/tr><tr><td><strong>Development<\/strong><\/td><td>Independent R&amp;D<\/td><td>Novel humanized IL-17 monoclonal antibody<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-strategy\" class=\"wp-block-heading\">Drug Profile &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Gumokimab (AK111, brand name Qiyoukang)<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>IL-17 (interleukin-17)<\/strong> pathway<\/li>\n\n\n\n<li><strong>Class:<\/strong> <strong>Novel humanized monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Development:<\/strong> <strong>Independently developed<\/strong> by Akeso Biopharma with full intellectual property rights<\/li>\n\n\n\n<li><strong>Therapeutic Area:<\/strong> <strong>Autoimmune diseases<\/strong> with initial focus on inflammatory conditions<\/li>\n\n\n\n<li><strong>Commercial Status:<\/strong> Now available in Chinese market following first batch shipment<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Market Size<\/th><th>Competitive Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Plaque Psoriasis<\/strong><\/td><td>~6.5 million patients in China<\/td><td>Competes with established IL-17 inhibitors (secukinumab, ixekizumab) and newer biosimilars<\/td><\/tr><tr><td><strong>Ankylosing Spondylitis<\/strong><\/td><td>~4-5 million patients in China<\/td><td>Growing market with multiple biologic options; gumokimab would be among newest entrants<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>dual-indication strategy<\/strong> positions gumokimab to capture significant market share across two major autoimmune disease segments, leveraging Akeso&#8217;s established commercial infrastructure and physician relationships.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Diversification:<\/strong> Adds to Akeso&#8217;s growing portfolio of commercial-stage assets beyond oncology<\/li>\n\n\n\n<li><strong>Autoimmune Expansion:<\/strong> Establishes foothold in high-value chronic disease market with recurring treatment patterns<\/li>\n\n\n\n<li><strong>R&amp;D Validation:<\/strong> Demonstrates Akeso&#8217;s capability to successfully develop and commercialize complex biologics independently<\/li>\n\n\n\n<li><strong>Pipeline Momentum:<\/strong> Second indication under regulatory review provides near-term growth catalyst<\/li>\n\n\n\n<li><strong>Market Timing:<\/strong> Enters psoriasis market as healthcare system prioritizes chronic disease management and biologic access<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The successful first shipment marks a critical transition from development to commercial execution, with gumokimab expected to contribute meaningfully to Akeso&#8217;s revenue trajectory in 2026-2027.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and pipeline development. Actual results may vary based on market adoption, competitive dynamics, and regulatory timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[360,850,40],"class_list":["post-69042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-akeso-biopharma","tag-hkg-9926","tag-market-launch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso&#039;s latest commercial launch in the competitive autoimmune disease market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69042\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval\" \/>\n<meta property=\"og:description\" content=\"Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso&#039;s latest commercial launch in the competitive autoimmune disease market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69042\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T13:54:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-29T13:54:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval\",\"datePublished\":\"2026-06-29T13:54:39+00:00\",\"dateModified\":\"2026-06-29T13:54:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042\"},\"wordCount\":348,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2903.webp\",\"keywords\":[\"Akeso Biopharma\",\"HKG: 9926\",\"Market launch\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69042#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69042\",\"name\":\"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2903.webp\",\"datePublished\":\"2026-06-29T13:54:39+00:00\",\"dateModified\":\"2026-06-29T13:54:40+00:00\",\"description\":\"Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso's latest commercial launch in the competitive autoimmune disease market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69042\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2903.webp\",\"width\":1080,\"height\":608,\"caption\":\"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69042#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso's latest commercial launch in the competitive autoimmune disease market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69042","og_locale":"en_US","og_type":"article","og_title":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval","og_description":"Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso's latest commercial launch in the competitive autoimmune disease market.","og_url":"https:\/\/flcube.com\/?p=69042","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-29T13:54:39+00:00","article_modified_time":"2026-06-29T13:54:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69042#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69042"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval","datePublished":"2026-06-29T13:54:39+00:00","dateModified":"2026-06-29T13:54:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69042"},"wordCount":348,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69042#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp","keywords":["Akeso Biopharma","HKG: 9926","Market launch"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69042#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69042","url":"https:\/\/flcube.com\/?p=69042","name":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69042#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69042#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp","datePublished":"2026-06-29T13:54:39+00:00","dateModified":"2026-06-29T13:54:40+00:00","description":"Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed its first batch shipment in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with moderate-to-severe plaque psoriasis. The novel humanized IL-17 monoclonal antibody represents Akeso's latest commercial launch in the competitive autoimmune disease market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69042#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69042"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69042#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp","width":1080,"height":608,"caption":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69042#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69042"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69042\/revisions"}],"predecessor-version":[{"id":69044,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69042\/revisions\/69044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69043"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}